Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Stop trial intervention for boceprevir, PEG-IFN and RBV

"Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped."

Trial Locations (1)

80787

Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan., Kaohsiung City

All Listed Sponsors
collaborator

National Taiwan University Hospital

OTHER

lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT02060058 - Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy | Biotech Hunter | Biotech Hunter